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Drug allergy to antibiotics may occur in the form of immediate or non-immediate (delayed) hypersensitivity reactions. Immediate reactions are usual-
ly IgE-mediated whereas non-immediate hypersensitivity reactions are usually non-IgE or T-cell mediated. The clinical manifestations of antibiotic 
allergy may be cutaneous, organ-specific (e.g., blood dyscracias, hepatitis, interstitial nephritis), systemic (e.g., anaphylaxis, drug induced hypersen-
sitivity syndrome) or various combinations of these. Severe cutaneous adverse reactions manifesting as Stevens Johnson syndrome or toxic epider-
mal necrolysis (TEN) may be potentially life-threatening. The management of antibiotic allergy begins with the identification of the putative antibiot-
ic from a detailed and accurate drug history, complemented by validated in-vivo and in-vitro allergological tests. This will facilitate avoidance of the 
putative antibiotic through patient education, use of drug alert cards, and electronic medical records with in-built drug allergy/adverse drug reaction 
prescription and dispensing checks. Knowledge of the evidence for specific antibiotic cross-reactivities is also important in patient education. Apart 
from withdrawal of the putative antibiotic, immunomodulatory agents like high-dose intravenous immunoglobulins may have a role in TEN. Drug de-
sensitization where the benefits outweigh the risks, and where no alternative antibiotics can be used for various reasons, may be considered in cer-
tain situations. Allergological issues pertaining to electronic drug allergy alerts, computerized physician prescriptions and decision support systems, 
and antibiotic de-escalation in antimicrobial stewardship programmes are also discussed.
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INTRODUCTION
Antibiotics are one of the most common causes of drug aller-
gy in most epidemiological studies, both among adults and 
children.
1-6 Among the various classes of antibiotics, beta-lac-
tam antibiotics (penicillins and cephalosporins), cotrimoxazole 
and quinolones are some of the most common causes of anti-
biotic allergy.
Antibiotic allergy may occur in the form of immediate or non-
immediate (delayed) hypersensitivity reactions. Immediate re-
actions are usually IgE-mediated whereas non-immediate hy-
persensitivity reactions are usually non-IgE or T-cell mediated.
7 
The clinical manifestations of antibiotic allergy may be cutane-
ous, organ-specific (e.g., blood dyscracias, hepatitis, interstitial 
nephritis), systemic (e.g., anaphylaxis, drug induced hypersen-
sitivity syndrome) or various combinations of these. Severe cu-
taneous adverse reactions (SCAR) manifesting as Stevens John-
son syndrome (SJS) or toxic epidermal necrolysis (TEN) may be 
potentially life-threatening.
8
DIAGNOSIS OF ANTIBIOTIC ALLERGY
The management of antibiotic allergy begins with the identifi-
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cation of the putative antibiotic from a detailed and accurate 
drug history.
9 Not infrequently, the drug history may need to be 
obtained from a combination of sources other than the patient, 
including care-givers, records from other prescribing physi-
cians and both non-electronic and electronic medical records.
10 
With the use of digital photography, instructing patients to take 
digital photographs of the initial rash may become increasingly 
important in helping the allergist to diagnose a drug eruption, 
especially when the rash is likely to have resolved by the time 
the patient sees the allergist.
11-13
In the diagnosis of immediate allergic reactions to antibiotics, 
the in-vivo tests available are skin prick tests (SPT) and intrad-
ermal tests (IDT).
14,15 However, these have been well validated 
mainly for beta-lactam antibiotics and less so for other classes 
of antibiotics. For in-vitro tests, commercially available assays 
include fluorescent enzyme immunoassays (FEIA) (Immuno-
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CAP
®, Phadia) which are less sensitive and specific compared 
to skin tests. Again, these tests are available mainly for penicil-
lins and cephalosporins. Radioimmunoassays previously used 
mainly for the diagnosis of penicillin allergy (including the ra-
dioallergosorbent test, RAST) have over the years been replaced 
with the FEIA assays.
16,17 Flow-cytometric based basophil acti-
vation tests (BAT) (flow assay stimulation test, FAST/Flow-
CAST
®, Buhlmann Laboratories) which measure CD69 or 
CD203c on drug-specific activated basophils may have a role in 
the diagnosis of antibiotic allergy, with studies so far mainly fo-
cused on beta-lactam allergy.
18
For non-immediate reactions, delayed readings of IDT are 
done at 24 hours and 72 hours.
19 Delayed reactions are consid-
ered positive when there is an infiltrated erythematous reac-
tion. Patch tests are often done in Europe to assist in the diag-
nosis of non-immediate reactions to various antibiotics. The 
tests are read on day 2, day 4, and day 7 (if negative on days 2 
and 4), and the vehicle used is usually petrolatum.
20 The patch 
test allergens can be prepared in-house or using commercially 
available products (Chemotechnique Diagnostics
®, Sweden). 
However, the sensitivity of the test is usually drug- and reaction-
specific. Patch tests have been described in the diagnosis of 
non-immediate reactions to amoxicillin, cefcapene pivoxil, 
clindamycin, ciprofloxacin, clarithromycin, cotrimoxazole, 
doxycycline, erythromycin, fluoroquinolones, isoniazid, met-
ronidazole, minocycline, pristinamycin, rifampicin, spiramy-
cin, teicoplanin and vancomycin. Patch tests are generally use-
ful in maculopapular exanthema (MPE), eczema, acute gener-
alized exanthematous pustulosis (AGEP), fixed drug eruptions 
(FDE) (when done on the lesional skin), symmetric drug-relat-
ed intertriginous and flexural exanthema (SDRIFE, Baboon’s 
syndrome); but have not been shown to be very useful in SJS/
TEN and vasculitis.
19
In-vivo tests available for non-immediate reactions include 
the lymphocyte transformation test (LTT) which is a prolifera-
tion assay which detects drug-specific T-cells.
21 This test can be 
technically difficult to carry out and are thus often done in spe-
cialized centres, mostly in Europe. Like the patch test, the LTT is 
usually positive in a drug- and reaction-specific manner. Anti-
biotics which have been found to often test positive in LTT are 
beta-lactams, quinolones, macrolides, sulfonamides, tetracy-
cline, isoniazid and rifampicin. Similar to patch tests, LTT are 
often positive in MPE, bullous exanthema, AGEP, and drug rash 
with eosinophilia and systemic symptoms (DRESS). It is occa-
sionally positive in hepatitis and nephritis, but rarely positive in 
TEN, cytopaenias and vasculitis.
21,22 Novel in-vitro tests evaluat-
ing cytokine secretion, up-regulation of cell surface activation 
markers (e.g., CD69), and analysis of cytotoxic potential (gran-
zyme B, CD107) remain as research tools.
22
In view of the limited number of in-vivo and in-vitro tests 
commercially available for most antibiotics, and also because 
non-immediate reactions are generally more common than 
immediate reactions in clinical practice, drug provocation tests 
(DPT) often have to used in the diagnostic evaluation of drug 
allergy.
23-27 The indications for DPT are as follows:
23
to exclude hypersensitivity in non-suggestive history of drug  • 
hypersensitivity and in patients with non-specific symp-
toms, e.g. vagal symptoms following the use of an antibiotic
to provide safe pharmacologically and/or structurally non- • 
related drugs in proven hypersensitivity e.g. other antibiotics 
in beta lactam-allergic patients, anxious people who would 
refuse to take the recommended drug without proof of toler-
ance
to exclude cross-reactivity of related drugs in proven hyper- • 
sensitivity, e.g. a cephalosporin in a penicillin-allergic sub-
ject
to establish a firm diagnosis in suggestive history of drug hy- • 
persensitivity with negative, non-conclusive or non-avail-
able allergologic tests, e.g. MPE during aminopenicillin 
treatment with negative allergological tests.
DPT can generally be carried out safely with careful patient 
selection.
28 Blinded (single- or double-blind placebo-control) 
challenges may sometimes be needed in patients with non-
suggestive history and non-specific symptoms.
TREATMENT OF ANTIBIOTIC ALLERGY
Definitive treatment involves cessation of the suspected anti-
biotic. In certain instances where the antibiotic is required be-
cause there are no better alternatives (e.g., infection with multi-
resistant organisms, or when alternative drugs are more expen-
sive), drug desensitization can be carried out. Desensitization is 
a method of reintroducing antibiotics into highly sensitized pa-
tients to induce tolerance. However such individuals are still 
considered as being allergic to the antibiotic. Recent studies of 
in vitro rapid antigen desensitizations implicate mast cells and 
basophils as cellular targets, as well as syk, a signal transducing 
molecule, and signal transducer and activator of transcription 6 
(STAT6), which is responsible for the transcription of interleu-
kin (IL)-4 and IL-13.
29 Rapid desensitization results in patients 
achieving the target total dose of the drug through rapidly esca-
lating doses usually within 24 hours, slow desensitization re-
sults in patients achieving the total target dose within a few 
days to weeks. Desensitization should be avoided should the 
initial reaction be potentially life-threatening reactions like im-
munobullous eruptions and SJS/TEN, with the exception of 
anaphylaxis. Various desensitization protocols are available for 
penicillin (benzylpenicillin, ampicillin), cephalosporins (cef-
tazidime, cefotaxime), cotrimoxazole, ethambutol, imipenam, 
isoniazid, meropenam, metronidazole, rifamipicin, streptomy-
cin, vancomycin and fluoroquinolones.Allergy Asthma Immunol Res. 2010 April;2(2):77-86.  doi: 10.4168/aair.2010.2.2.77




Allergic reactions to beta-lactam antibiotics are the most 
common cause of drug allergies in most epidemiological stud-
ies on adverse drug reactions. SPT and IDT using commercially 
available penicilloyl polylysine (PPL), minor determinant mix 
(MDM) and benzylpenicillin G or amoxicillin have been vali-
dated in various studies and shown to be useful in the evalua-
tion of suspected immediate reactions to penicillin.
30,31 In 2004, 
Allergopharma and Hollister-Stier announced their decision to 
stop the commercial production of penicillin reagents (Aller-
gopen
® and PrePen
® respectively). A Spanish product (Diater
®) 
was subsequently found to be a reliable and consistent alterna-
tive
32,33 and is presently used in many countries worldwide. In 
September 2009, Pre-Pen
® was approved for marketing by the 
Food and Drug Administration (FDA) through ALK-Abello and 
Allerquest LLC. In countries where commercial PPL and MDM 
are not available, skin testing with benzylpenicillin may be used 
in lieu.
34 However, this may miss patients who may have tested 
positive to PPL or MDM, and thus could result in potentially 
positive drug provocation tests being done.
In-vitro tests are often less sensitive and more expensive when 
compared to skin tests, with the FEIA currently being the most 
widely commercially available test. The determinants used in 
FEIA are benzylpenicilloyl and amoxicilloyl. However, the sen-
sitivity (42-74%) and specificity (85-100%) reported varied 
among studies,
35,36 depending on when the sample was taken 
from the time of the initial clinical reaction, and the outcomes 
of skin tests to PPL, MDM and/or amoxicillin in the respective 
studies.
The flow cytometric BAT assay, when used in the diagnosis of 
beta-lactam allergy, has a sensitivity of 50%, and specificity of 
93%.
37,38 However, the test is unable to differentiate between se-
lective reactors and cross-reactors, and tests become negative 
the longer the duration from the initial reaction.
39 Using a com-
bination of skin tests, specific IgE assays, followed by cellular 
tests in negative patients, can facilitate confirmation of beta-
lactam allergy, avoiding DPT in up to two-thirds of patients.
40 
Using an alternative marker like CD203c may increase the sen-
sitivity of these tests.
41
Patch tests when used, should be carried out with benzylpeni-
cillin, amoxicillin, ampicillin, and any suspect penicillins and/
or cephalosporins. LTT for beta lactam allergy has a low sensi-
tivity of 60-70%, hence a positive test is useful in confirming beta 
lactam allergy but a negative test does not rule it out. The LTT is 
often positive in AGEP and DRESS, but rarely positive (<10%) in 
blood dyscracias and TEN associated with drug allergy.
42
Cephalosporin allergy
The reported cross-reactivity for IgE-mediated hypersensitivi-
ty between cephalosporins and penicillins in patients with Ig-E 
mediated penicillin allergy of 5-10%, were based on early stud-
ies from the 1970s on patients with a history of penicillin allergy 
who developed allergic reactions to cephalexin, cephalothin 
and cephaloridine.
43,44 In addition, early cephalosporin antibi-
otics contained traces of penicillin.
45 Although the practice pa-
rameters of the AAAAI in 1999 did not advocate the use of ce-
phalosporin skin testing,
27 this is recommended by the British 
Society of Allergy and Clinical Immunology (BSACI)
46 and the 
European Academy of Allergy and Clinical Immunology (EAA-
CI).
14 The R1 side chain rather than the betalactam structure, 
shared by penicillins and cephalosporins, seems to play a dom-
inant role in determining the specificity of immunologic reac-
tions to cephalosporins.
47 Thus, penicillin can be administered 
safely to patients allergic to cephalosporins and with a negative 
skin test result to penicillin determinants.
48 Similarly, this may 
the reason why the penicillin allergic individuals appear to be 
able to tolerate most third and fourth generation cephalosporins.
The flow cytometric BAT assay appears to be a promising in-




Earlier studies from the late 1980s showed that cross-reactivity 
between penicillin and imipenem allergy was 50% based on 10 
of 20 patients with penicillin allergy being skin test positive to 
one or more penicillin or imipenem determinants.
49 Recent 
prospective studies in adults and children with penicillin (pre-
dominantly amoxicillin) IgE-mediated allergy have shown that 
the cross-reactivity based on positive skin tests to imipenam-
cilastatin
50 and meropenam
51,52 was 0.9%, and that patients who 
were SPT/IDT negative to imipenam-cilastatin and merope-
nam were able to tolerate a graded, challenge dose of intrave-
nous imipenam-cilastatin and meropenam respectively. For 
delayed reactions to carbapenams, the cross-reactivity with 
penicillins was 5.5% based on patients with cell-mediated aller-
gy to penicillins showing positive patch tests to at least one 
penicillin reagent and imipenem-cilastatin. All patients with 
negative patch test and delayed IDT reading to imipenam-
cilastatin tolerated an intramuscular provocation test.
53
COTRIMOXAZOLE ALLERGY
Cotrimoxazole is an immunogenic drug which may cause 
both immediate and non-immediate reactions. Non-immedi-
ate reactions range from mild MPE and FDE to serious SJS and 
TEN,
54,55 and are more common than immediate reactions. This 
is especially prevalent in HIV-infected individuals where cotri-
moxazole is used for the treatment and prophylaxis for Pneu-
mocystis jiroveci infection and toxoplasmosis.
56 Slow acetylator 
phenotype and genotype,
57,58 and major histocompatibility 
complex (MHC) polymorphisms
59 have not been shown to be 
major predisposing risk factors for cotrimoxazole hypersensi-Allergy Asthma Immunol Res. 2010 April;2(2):77-86.  doi: 10.4168/aair.2010.2.2.77
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tivity in HIV-infected individuals. Rapid and slow desensitiza-
tion to cotrimoxazole especially in the setting of HIV infection, 
has been shown to be effective and safe.
60
FLUOROQUINOLONE ALLERGY
Fluoroquinolone allergy may present in the form of immedi-
ate and non-immediate reactions. The immediate reactions 
may be IgE mediated or non IgE mediated, with non-IgE medi-
ated reactions occurring after the first dose with no previous 
history of sensitization.
61,62 Although previous studies had 
shown that skin tests to quinolones lack sensitivity and specific-
ity,
63 a negative skin test could predict a negative challenge test 
in 94% of the challenged cases.
64 Cross-reactivity has been 
demonstrated for immediate reactions through positive skin 
tests to a range of quinolones,
62 and delayed reactions through 
generation and analysis (flow cytometry and proliferation as-
says) of quinolone-specific T cell clones respectively.
65 Thus, 
patients with allergy to a fluoroquinolone should avoid other 
fluoroquinolones.
MACROLIDE ALLERGY
Macrolides are classified according to the number of carbon at-
oms in the chemical structure: 14 membered (erythromicin, rox-
ithromycin, dirithromycin, clarithromycin), 15 membered (azi-
thromycin) and 16 membered (spiramycin, josamycin, mide-
camycin) macrolides. Allergic reactions to macrolide antibiotics 
appear to be relatively uncommon (0.4% to 3% of treatments).
66 
Cases of immediate reactions in the form of anaphylaxis,
67 and 
non-immediate reactions like fixed drug eruptions, toxic epider-
mal necrolysis and leukocytoclastic vasculitis have been report-
ed, in children and adults, for clarithromycin and azithromycin. 
Successful desensitization has also been reported.
68
TETRACYCLINE ALLERGY
Minocycline can cause serious adverse reactions including 
drug hypersensitivity syndrome, serum sickness and drug-in-
duced lupus. These occur on average within 4 weeks of therapy, 
whereas minocycline-induced lupus occurs on average 2 years 
after the initiation of therapy.
69 Apart from photodermatoses 
and photo-onycholysis which are usually phototoxic in nature, 
adverse drug reactions, in particular drug allergies to doxycy-
cline and tetracycline are relatively rare.
70
CLINDAMYCIN ALLERGY
Clindamycin may be associated with both immediate and 
non-immediate allergic reactions.
71 However, the prevalence of 
such reactions is rare.
72 Apart from exanthematous eruptions, 
cases reported in the literature include contact dermatitis, 
AGEP
73 and TEN.
74 The use of a combination of skin prick tests, 
patch tests and oral challenges if skin tests are negative, appear 
to be more useful compared to SPT and IDT alone as negative 
skin tests may still result in positive challenges.
75,76 Clindamycin 
desensitization has been reported in the literature in particular 
in HIV-infected individuals.
77,78
VANCOMYCIN AND TEICOPLANIN ALLERGY
Vancomycin, a glycopeptide, has rarely been reported to be 
associated with allergic drug reactions including exfoliative 
dermatitis and maculopapular rash. This is in contrast to van-
comycin red man syndrome, which is commonly associated 
with too rapid an infusion of vancomycin resulting in direct 
mast cell histamine release.
79
Anaphylaxis from vancomycin may be through IgE mediated 
allergic mechanisms or non-IgE mediated non-allergic mecha-
nisms. Various effective desensitization regimes have been de-
scribed in the treatment of vancomycin anaphylaxis.
80-83
Linear IgA bullous dermatosis (LABD) is an autoimmune, 
subepidermal, vesiculobullous disease that has been common-
ly associated with the use of vancomycin.
84,85 Lesions typically 
appear during vancomycin therapy, 24 hours to 15 days after 
the first dose. Histopathologic examination and immunofluo-
rescence studies are diagnostic, showing linear IgA and C3 de-
posits at the basement membrane zone on direct immunofluo-
rescence. Withdrawal of vancomycin is all that is required.
Teicoplanin, another glycopeptide, has fewer side effects 
compared to vancomycin.
79 Red man syndrome is very unusual 
with teicoplanin because this compound does not cause hista-
mine release even at faster infusion rates than those of vanco-





90] are infrequent. Al-
though there have been reports of cross-reactivity between in-
dividuals with vancomycin and teicoplanin allergy,
91-95 there 
have also been reports of patients with teicoplanin who tolerat-
ed vancomycin.
96,97
Pre-operative allergy clinic assessment together with penicil-
lin skin testing has been shown to be an effective intervention 
in reducing unnecessary use of prophylactic vancomycin peri-
operatively.
98,99 This would be helpful in the long-term in reduc-
ing the spread of vancomycin resistant infections in hospitals 
and within the community, and the need for potentially expen-
sive antibiotics like linezolid and tigecycline.
TUBERCULOUS DRUG ALLERGY
Mycobacterium tuberculosis (MTC) infection remains endem-
ic in certain parts of Asia. Treatment of MTC infections involves 
combinations of anti-tuberculous drugs including isoniazid, ri-
fampicin, ethambutol and pyrazinamide. Non-immediate re-
actions are much more common than immediate reactions to Allergy Asthma Immunol Res. 2010 April;2(2):77-86.  doi: 10.4168/aair.2010.2.2.77
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anti-tuberculous drugs. Drug eruptions
100 in the form of MPE 
and lichenoid drug eruptions,
101 haematological reactions, 
hepatitis, DHS, SJS/TEN
102,103 have all been reported in the liter-
ature. Diagnosis using LTT have not been useful to date.
104-106 
Patch tests are also not consistently useful as they are depen-
dent on the type of cutaneous drug eruption.
19,20 In practice, it is 
often not clinically feasible to leave MTC infection untreated for 
6 weeks pending evaluation using LTT or patch tests, which in 
the end may not be helpful. As such, rapid oral desensitization 
regimes have been described for isoniazid, rifampicin and 
ethambutol.
107-111 These regimes often involve reintroducing the 
anti-tuberculous drugs as soon as the allergic reaction has set-
tled. In addition, more than one drug often needs to be reintro-
duced, with at most a 3-5 day interval apart, because leaving 
patients on anti-tuberculous monotherapy would increase the 
risk of emergence of drug-resistant tuberculosis. If the initial al-
lergic reaction was SJS/TEN, desensitization would need to be 
considered very carefully in consultation with the attending in-
fectious diseases physician or pulmonologist. The risks of de-
sensitization need to be explained carefully to the patient pro-
vided combinations of second-line anti-tuberculous drugs (e.g., 
quinolones, dapsone, cycloserine) are not an option.
SEVERE CUTANEOUS ADVERSE REACTIONS (SCAR)
Severe cutaneous adverse reactions (SCAR) include SJS, TEN 
and DHS or DRESS).
8 In the study of Roujeau et al.,
54 sulfon-
amides were the most strongly associated with TEN, followed 
by antibiotic drugs (in descending order of frequency: cepha-
losporins, quinolones, aminopenicillins, tetracyclines, mac-
rolides), imidazole antifungals, anticonvulsants (phenobarbital, 
phenytoin, valproic acid, carbamazepine, and lamotrigine), 
then nonsteriodal anti-inflammatory drugs (especially oxicam) 
and allopurinol. HLA B*38 showed only a weak association 
with sulfamethoxazole induced SJS/TEN
54 in contrast to anti-
epileptic drugs and allopurinol where HLA associations are 
stronger and ethnically related.
112
In DHS, systemic corticosteroids (0.5 to 1 mg/kg/day) tapered 
over 6-8 weeks rapidly improves symptoms and laboratory 
measurements, but its impact on the long term disease course 
is not known. Controlled clinical trials are lacking on the use of 
systemic corticosteroids in DHS. Relapses of rash and hepatitis 
may occur as corticosteroids are tapered.
113 Sequential reactiva-
tion of herpes viruses (e.g., human herpes virus 6, Ebstein Barr 
virus, cytomegalovirus)
114 and subsequent triggering of autoim-
munity
115 may explain these relapses, and hence the effective-
ness of systemic corticosteroids.
In SJS, the use of systemic corticosteroids has been supported 
by case reports and series (prospective and retrospective) 
which showed positive outcomes with the early use of corticos-
teroids (prednisolone 1 mg/kg/day or methylprednisolone 1-2 
mg/kg/day) within 72 hours was beneficial in arresting the pro-
gression of SJS.
116-120 However, there were also other studies 
which showed harm or no benefit.
121
TEN is defined as the detachment of the epidermis affecting 
more than 30% body surface area of skin involvement. In early 
TEN, between 10-30% of epidermal detachment occurs which 
can sometimes be diagnosed clinically from a positive Nikol-
sky’s sign or histological evidence of epidermal necrolysis. 
Apart from prompt withdrawal of the suspected drug, support-
ive measures including specialized nursing, early referral to a 
specialized unit, nutritional and respiratory care and support, 
skin care including the use of Biobrane dressings, are standard 
of care for which there are no controlled trials.
122 Systemic corti-
costeroids should not been used as most series have suggested 
that the risks outweigh the benefits. The use of oral and intrave-
nous cyclosporine 3-5 mg/kg/day, of duration of up to 3 weeks 
in case series of patients with severe TEN suggest that the risks 
of infection outweighed the benefits.
123-125 The only double-
blind placebo-controlled trial to date in the management of 
TEN, using thalidomide was stopped because there was exces-
sive mortality in the thalidomide group.
126 Other therapies like 
cyclophosphamide
127 and plasmapharesis
128 have not been 
shown to be useful.
In the last decade, several case series
129-133 have described the 
use of high dose intravenous immunoglobulins (IVIg) from 0.8-
3 g/day in the treatment of TEN. The rationale for the use of 
IVIg is based on the inhibition of Fas-mediated keratinocyte 
apoptosis in TEN by naturally occurring Fas-blocking antibod-
ies within the IVIg. Although there were wide variation in pa-
tients and treatment protocols, different brands of IVIg used 
with different dosing regimens, the overall mortality rate was 
around 20% with earlier re-epithelialization demonstrated in 
some of the studies.
The prevalence of acute ocular complications ranges from 6% 
to 100%, and long-term sequelae from 1% to 50%. The most 
common long-term sequelae is sicca syndrome. Others include 
corneal ulceration, corneal epithelial defect, symblepharon and 
fornix foreshortening. Treatment modalities for ocular compli-
cations include topical antibiotics, topical corticosteroids, lu-
bricants, and fornix sweeping. High-dose IVIg did not appear to 
reduce the severity of visually significant ocular complica-
tions.
134 Early intervention with cryopreserved amniotic mem-
brane transplantation was shown in a recent study to suppress 
inflammation and promote epithelial healing at the acute 
stage.
135 Significant dry eye problems and photophobia may 
also be avoided with this intervention.
A recent retrospective study from China suggested that com-
bination therapy with corticosteroid and high dose IVIG exhib-
ited a tendency to reduce the mortality rate in comparison with 
administration of corticosteroid alone. The decrease in the 
mortality rate, however, was not statistically significant. Combi-
nation therapy also arrested progression earlier and decreased 
the hospitalization time, meaning that the total dose of corti-Allergy Asthma Immunol Res. 2010 April;2(2):77-86.  doi: 10.4168/aair.2010.2.2.77
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costeroid may be reduced. Combination therapy, however, did 
not lead to earlier tapering of corticosteroid.
136
DRUG-INDUCED LUPUS
Drug-induced lupus erythematosus (DILE) is defined as a lu-
pus-like syndrome temporally related to continuous drug expo-
sure which resolves after discontinuation of the offending drug. 
There are currently no standard diagnostic criteria for DILE and 
the pathomechanisms are still unclear. Among the antibiotics, 
minocycline and isoniazid are most often associated with DILE. 
Systemic DILE is characterized by typical lupus-like symptoms 
including skin signs, usually mild systemic involvement and a 
typical laboratory profile with positive antinuclear and anti-his-
tone antibodies. In most cases of classic DILE, visceral involve-
ment, low serum complement levels as well as anti-extractable 
nuclear antigen antibodies and anti-dsDNA antibodies are 
rarely present. In contrast, these are present in half the cases of 
anti-tumour necrosis factor (TNF) alpha inhibitor induced 
DILE. The diagnosis of DILE is based on a temporal association 
(months to years) of use of the putative drug with characteristic 
lupus-like symptoms, and resolution of symptoms upon with-
drawal of the drug. Systemic corticosteroids and immunosup-
pressive drugs are only needed in refractory cases.
137
ANTIBIOTIC ALLERGY AND ANTIMICROBIAL 
STEWARDSHIP PROGRAMMES
Antimicrobial stewardship programs in hospitals seek to opti-
mize antimicrobial prescribing in order to improve individual 
patient care, reduce hospital costs and slow the spread of anti-
biotic resistant organisms. Such programs are often adminis-
tered by multidisciplinary teams comprising infectious diseases 
physicians, clinical pharmacists, clinical microbiologists, and 
infection control practitioners. Strategies for changing antimi-
crobial prescribing behaviour include education of prescribers 
regarding proper antimicrobial usage, creation of an antimicro-
bial formulary with restricted prescribing of targeted agents, 
and review of antimicrobial prescribing with feedback to pre-
scribers. De-escalation from broad-spectrum empirical antibi-
otics to narrow-spectrum, culture and sensitivity specific anti-
biotic is a supplemental strategy used in such programmes to 
reduce antibiotic resistance from the use of broad-spectrum 
antibiotics.
138 However, de-escalation in a patient with uncon-
firmed antibiotic allergy should be exercised with caution as 
drug provocation tests in the presence of negative skin tests, 
should be avoided in the presence of on-going sepsis unless no 
other alternative antibiotics are available.
23 Similarly, in the pa-
tient with a high probability of allergy to a narrow spectrum an-
tibiotic (e.g., penicillin G) who has been tolerating a broad-
spectrum antibiotic (e.g., meropenam), it would be prudent to 
continue the broad-spectrum antibiotic rather than to consider 
skin testing and desensitization to penicillin G in the presence 
of on-going sepsis where alternative antibiotic choices remain 
available.
ANTIBIOTIC ALLERGY ALERTS AND DECISION SUPPORT 
FOR COMPUTERIZED PHYSICIAN ORDERS
Antibiotic stewardship programmes may also be comple-
mented by electronic computerized physician prescriptions 
with decision support systems
139 utilizing drug/antibiotic aller-
gy checks.
140 However, the data from electronic drug allergy 
physician reporting systems are often inaccurate or incomplete. 
Thus, using such electronic alerts in any type of electronic med-
ication record system as a decision support tool to facilitate an-
tibiotic prescribing has to be done very cautiously.
CONCLUSIONS
Antibiotics may cause various types of allergic drug reactions 
ranging from mild to serious cutaneous reactions, organ-spe-
cific or systemic reactions. A high index of clinical suspicion 
and immediate withdrawal of the suspected drug/drugs are the 
most important steps in the management of antibiotic allergy. 
Systemic immunomodulatory drugs may be required to sup-
press severe cutaneous/systemic reactions. Drug desensitiza-
tion may be considered in cases where the risks of retrying the 
drug outweigh the benefits, in particular where no alternative 
medications are available or are as effective.
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